share_log

Cantor Fitzgerald Reiterates Overweight on X4 Pharmaceuticals, Maintains $3 Price Target

Benzinga ·  Mar 26 14:12

Cantor Fitzgerald analyst Kristen Kluska reiterates X4 Pharmaceuticals (NASDAQ:XFOR) with a Overweight and maintains $3 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 220

Recommended

Write a comment